Drug Price Negotiation Proposals Undermine Current Bipartisan Approaches to Lower Drug Spending
Congress is actively seeking to advance legislation to allow the Medicare program to “negotiate” the prices of brand drugs. However, these proposals neglect to consider the impact on the development of lower-cost generic and biosimilar medicines.